The survival benefits of antiretroviral therapy in South Africa

Journal of Infectious Diseases

Volumn 209, Issue 4, 2014, Pages 491-499

  April, Michael D ^a,b   Wood, Robin ^i,j   Berkowitz, Bethany K ^b   Paltiel, A David ^h   Anglaret, Xavier ^k,l,m   Losina, Elena ^b,e   Freedberg, Kenneth A ^b,c,d,f   Walensky, Rochelle P ^b,d,g  

^a San Antonio Uniformed Services Health Education Consortium   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d Department of Medicine   (United States)

^e Department of Biostatistics ^*  (United States)

^f BOSTON UNIVERSITY   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h YALE UNIVERSITY   (United States)

ⁱ Institute of Infectious Disease and Molecular Medicine   (United States)

^j UNIVERSITY OF CAPE TOWN   (South Africa)

^k Centre 897   (South Africa)

^l UNIVERSITÉ DE BORDEAUX   (France)

^m Programme PAC CI ANRS Research Site in Abidjan   (France)

more..

Author keywords

highly active antiretroviral therapy; HIV; South Africa

Indexed keywords

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV; SOUTH AFRICA;

ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; SOUTH AFRICA; VIRAL LOAD;

EID: 84893307251     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit584     Document Type: Conference Paper

References (48)

1. Joint United Nations Programme on HIV/AIDS. AIDSinfo database. Geneva: Joint United Nations Programme on HIV/AIDS, 2012. http ://www.unaids.org/en/ dataanalysis/tools/aidsinfo/. Accessed 4 August 2013.
2. National Department of Health South Africa. National antiretroviral treatment guidelines. Pretoria: Jacana, 2004. http://southafrica. usembassy.gov/media/2004-doh-art-guidelines.pdf. Accessed 4 August 2013.
3. National Department of Health South Africa. The South African antiretroviral treatment guidelines. Pretoria: South African National AIDS Council, 2010. http://sonkepharmaceuticals.co.za/images/stories/documents/the- south-african-antiretroviral-treatment-guidelines.pdf. Accessed 4 August 2013.
4. United Nations General Assembly. Political declaration on HIV and AIDS: intensifying our efforts to eliminate HIV and AIDS. New York, NY: United Nations General Assembly, 2011. http://www.unaids.org/en/media/unaids/contentassets/ documents/document/2011/06/20110610-un-a-res-65-277-en.pdf. Accessed 4 August 2013.
5. National Department of Health. Operational plan for comprehensive HIV and AIDS care, management and treatment for South Africa. Pretoria: National Department of Health, 2003. http://www.info.gov.za/otherdocs/2003/aidsplan/ index.html. Accessed 4 August 2013.
6. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS, 2012. http://www.unaids.org/en/media/unaids/contentassets/documents/ epidemiology/2012/gr2012/20121120-UNAIDS-Global-Report-2012-en.pdf. Accessed 4 August 2013.
7. Cohen RL, Li Y, Giese R, Mancuso JD. An evaluation of the President's Emergency Plan for AIDS Relief effect on health systems strengthening in sub-Saharan Africa. J Acquir Immune Defic Syndr 2013; 62:471-9.
8. Bendavid E, Holmes CB, Bhattacharya J, Miller G. HIV development assistance and adult mortality in Africa. JAMA 2012; 307:2060-7.
9. Bor J, Herbst AJ, Newell ML, Barnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 2013; 339:961-5.
10. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11-9.
11. Walensky RP, Wood R, Fofana MO, et al. The clinical impact and costeffectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr 2011; 56:26-35.
12. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings-the case of Côte d'Ivoire. N Engl J Med 2006; 355:1141-53.
13. Walensky RP, Wood R, Weinstein MC, et al. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis 2008; 197:1324-32.
14. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4:e298.
15. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010; 15(Suppl 1):1-15.
16. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
17. Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006; 42:464-9.
18. United Nations Department of Economic and Social Affairs Population Division. World population prospects: the 2008 revision. New York: United Nations, 2009. http://www.un.org/esa/population/publications/wpp2008/wpp2008- highlights.pdf. Accessed 4 August 2013.
19. Yazdanpanah Y, Losina E, Anglaret X, et al. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS 2005; 19: 1299-308.
20. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Geneva:World Health Organization, 2006. http ://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. Accessed 4 August 2013.
21. World Health Organization. Progress report 2011: global HIV/AIDS response. Geneva: World Health Organization, 2011. http://www.who.int/hiv/pub/ progress-report2011/en/index.html. Accessed 4 August 2013.
22. Ahonkhai AA, Noubary F, Munro A, et al. Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. PLoS One 2012; 7:e32993.
23. Morrow C, Munro A, Wilke M, Stark R, Wood R. Remote sensing of HIV care programmes using centrally collected laboratory results: canwe monitor ART programme effectiveness?. S Afr Med J 2012; 102:501-5.
24. Losina E, Yazdanpanah Y, Deuffic-Burban S, et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire. Antivir Ther 2007; 12:543-51.
25. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10:155-66.
26. Tuboi SH, Brinkhof MW, Egger M, et al. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 2007; 45:52-9.
27. World Health Organization. Towards universal access. Geneva: World Health Organization, 2010. http://whqlibdoc.who.int/publications/2010/9789241500395- eng.pdf. Accessed 4 August 2013.
28. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resourcelimited settings: systematic review and meta-analysis. PLoS One 2009; 4:e5790.
29. Van Cutsem G, Ford N, Hildebrand K, et al. Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS One 2011; 6:e14684.
30. Nglazi MD, Lawn SD, Kaplan R, et al. Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr 2011; 56:e1-8.
31. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings. Geneva: WHO, 2002. http://www.who.int/hiv/pub/prev- care/en/ScalingUp-E.pdf. Accessed 4 August 2013.
32. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Geneva:World Health Organization, 2010.
33. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-95.
34. Seyler C, Anglaret X, Dakoury-Dogbo N, et al. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire. Antivir Ther 2003; 8:385-93.
35. Hammond R, Harry TC. Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures-a metaanalysis. Int J STD AIDS 2008; 19:291-6.
36. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-60.
37. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19:685-94.
38. Actuarial Society of South Africa. ASSA2008 model. Cape Town, South Africa: Actuarial Society of South Africa, 2011. http://aids. actuarialsociety.org.za/Models-3145.htm. Accessed 4 August 2013.
39. Lawn SD, Myer L, Harling G, et al. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006; 43:770-6.
40. Stover J, Korenromp EL, Blakley M, et al. Long-term costs and health impact of continued global fund support for antiretroviral therapy. PLoS One 2011; 6:e21048.
41. Resch S, Korenromp E, Stover J, et al. Economic returns to investment in AIDS treatment in low and middle income countries. PLoS One 2011; 6:e25310.
42. Joint United Nations Programme on HIV/AIDS. What countries need-investments needed for 2010 targets. Geneva: Joint United Nations Programme on HIV/AIDS, 2009. http://data.unaids.org/pub/Report/2009/jc1681-what- countries-need-en.pdf. Accessed 4 August 2013.
43. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-63.
44. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011; 8:e1001056.
45. April MD. Rethinking HIV exceptionalism: the ethics of opt-out HIV testing in sub-Saharan Africa. BullWorld Health Organ 2010; 88:703-8.
46. Shisana O, Rehle T, Simbayi L, et al. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2008. Cape Town: HSRC Press, 2009. http://www.mrc.ac.za/pressreleases/2009/sanat.pdf. Accessed 4 August 2013.
47. Ciaranello AL, Perez F, Engelsmann B, et al. Cost-effectiveness of World Health Organization 2010 guidelines for prevention of motherto-child HIV transmission in Zimbabwe. Clin Infect Dis 2013; 56: 430-46.
48. Meyer-Rath G, Brennan A, Long L, et al. Cost and outcomes of paediatric antiretroviral treatment in South Africa. AIDS 2013; 27:243-50.